Study identifies potential RAS inhibitor-immunotherapy strategy for pancreatic cancer

Дата публикации: 23-09-2026 21:20:01

Pancreatic cancer does not respond to most immunotherapies, but RAS inhibitors could alter tumors to make them more sensitive to a novel immunotherapeutic approach. In pancreatic tumors with RAS mutations, RAS inhibitors cause massive cell death and reduce immunosuppression. These changes tend to be temporary because tumors develop resistance to the therapy.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Making invisible cancers visible: A new route to turn 'cold' tumors 'hot'	0	7.83	17-09-2026
2	Metabolic activity of gut bacteria can either promote or inhibit function of CAR T cells in cancer therapy	0	6.96	28-09-2026
3	Cancer biologists bring in the B-cell reinforcements for immunotherapy	0	8.93	17-09-2026
4	Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer	0	9.74	24-08-2026
5	From professor to patient: One man's journey on the frontier of lung cancer treatment	0	7.28	27-09-2026
6	From professor to patient: One man's journey on the frontier of lung cancer treatment	0	7.28	27-09-2026
7	Study of the effect of 1-({4-[(2,4-dichlorobenzoyl)amino]phenyl}sulfonyl-(2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid (GGM-27) on tumor growth and survival in BALB/c mice bearing ACATOL colon adenocarcinoma in comparison with doxorubicin	0	5.45	29-06-2026
8	Immunotherapy increases risk for major cardiovascular events	0	10.61	23-09-2026
9	GSK’s B7-H3-targeted antibody-drug conjugate, risvutatug rezetecan, granted Orphan Drug Designation for small-cell lung cancer in Japan	0	14.91	23-03-2026
10	A blood-based approach could enable personalized immunotherapy without the need for a tumor biopsy	0	10.91	29-09-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 7.48. Источник: medicalxpress.com.